LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
Purity
Page 3 of 51 of this archive, newest first.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
PeptideMeter result on a Changsha mazdutide lot lands 4.4 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
What changed at QST in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
When a better instrument changes the answer rather than the confidence
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
Independent analysis puts a Homopeptide retatrutide lot at 98.3%, against 97.3% on the certificate
The result is unremarkable. What the report omits is not.
What changed at WXT in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The pyrogen question has a price, and it is not the price of a purity run
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What changed at SWB in May, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a ERP orforglipron lot at 98.6%, against 97.6% on the certificate
The result is unremarkable. What the report omits is not.
Independent analysis puts a FGP tirzepatide lot at 96.0%, against 93.3% on the certificate
The result is unremarkable. What the report omits is not.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Independent analysis puts a Homopeptide semaglutide lot at 98.1%, against 95.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
Five things a purity figure cannot tell you
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Poland health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
We asked four laboratories for a sterility test. Here is what came back.
We asked all four services what they can determine, on what timescale, at what price, and under what accreditation. The answers are printed in full.
Independent analysis puts a TFC semaglutide lot at 96.7%, against 94.6% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.